Eric Singer

In this discussion, Dr. Eric Singer, lead author and expert from the Ohio State University Comprehensive Cancer Center, provides insights on the ASCO guidelines for managing metastatic renal clear cell cancer. He reviews the impactful findings from the COSMIC 313 trial, especially regarding triplet therapy, while cautioning against its potential toxicity. Emphasis is placed on balancing treatment efficacy with patient safety, advocating for established doublet therapies. The conversation also points to future clinical trials and ongoing questions that remain in the field.